Fosamax Restarting After Acute Illness: When to Resume Alendronate Safely

Why Acute Illness Forces an Alendronate Hold in the First Place

Acute illness disrupts nearly every prerequisite for safe alendronate dosing. The drug requires the patient to swallow it with 6 to 8 oz of plain water, remain fully upright for at least 30 minutes, and avoid all other food, beverages, and medications for 30 to 60 minutes afterward. Hospitalized or bedridden patients frequently cannot meet any of those conditions safely.

The Physiological Reasons for Holding the Drug

Alendronate is a potent nitrogen-containing bisphosphonate that inhibits farnesyl pyrophosphate synthase in osteoclasts, driving osteoclast apoptosis and suppressing bone resorption. Oral bioavailability is already only 0.6% under ideal fasting conditions; co-administration with food, antacids, or calcium reduces absorption by up to 60%. Nausea, vomiting, or dysphagia during acute illness makes proper administration nearly impossible and raises the risk of esophageal irritation.

Acute illness also frequently produces transient renal impairment. Because alendronate is eliminated exclusively by the kidneys without hepatic metabolism, the FDA prescribing information for alendronate sodium contraindications use when eGFR falls below 35 mL/min/1.73 m². An acute kidney injury episode that crosses this threshold is an absolute reason to hold the drug until renal function recovers.

Esophageal Risk During Illness

Alendronate carries a boxed warning for severe esophageal reactions, including esophagitis, esophageal ulcers, and esophageal erosions. Patients who are sedated, obtunded, have active vomiting, or cannot sit upright face materially higher risk if a dose is taken incorrectly. Holding the drug until upright posture is restored is standard practice endorsed by the American College of Rheumatology and consistent with the drug's labeling.

The Fracture Risk Equation: Why Restarting Matters

Short treatment gaps are clinically meaningful. Alendronate's anti-fracture benefit is well-documented across multiple large randomized trials, and bone turnover markers begin rising within weeks to months of discontinuation.

FIT Trial Data

The Fracture Intervention Trial (FIT) remains the key efficacy dataset for alendronate. Published in JAMA 1998 (N=2,027 postmenopausal women with low bone density), FIT demonstrated a 47% relative risk reduction in morphometric vertebral fractures (relative risk 0.53, 95% CI 0.41 to 0.68) over 3 years of continuous alendronate therapy compared with placebo. Hip fracture risk fell by 51% in the subgroup with pre-existing vertebral fractures.

Those numbers establish what continuous therapy can achieve. Any unnecessary prolongation of a treatment hold erodes that protection.

Bone Turnover Marker Rebound

Biochemical markers of bone resorption, specifically serum C-telopeptide (CTX) and urine N-telopeptide (NTX), begin rising within 3 to 6 months of alendronate discontinuation and may return to pre-treatment levels within 12 to 18 months in some patients. A 2 to 4 week hold during acute illness does not produce a clinically meaningful rebound. Holds extending beyond 3 months warrant reassessment.

Bone Mineral Density Persistence

One advantage of alendronate over some other osteoporosis agents is that bone mineral density (BMD) gains are relatively durable after short discontinuation. A 10-year extension of the FIT trial (FLEX trial, N=1,099) found that women who discontinued alendronate after 5 years maintained BMD above pre-treatment baseline for at least 5 additional years, though bone turnover markers rose modestly. This pharmacokinetic "reservoir" effect in bone tissue provides some protection during short illness-related holds.

Pre-Restart Checklist: What to Confirm Before the First Dose Back

Resuming alendronate without a brief clinical reassessment is a missed opportunity. A systematic pre-restart evaluation takes less than 10 minutes and prevents re-admission for avoidable adverse events.

Laboratory Parameters

Order the following before restarting:

• eGFR: Must be above 35 mL/min/1.73 m². The FDA label is explicit that alendronate is not recommended below this threshold due to lack of safety and efficacy data.
• Serum calcium (corrected for albumin): Hypocalcemia must be corrected before bisphosphonate therapy is resumed. A 2019 review in the Journal of Bone and Mineral Research confirmed that bisphosphonate-induced hypocalcemia is more severe and prolonged when pre-treatment calcium is already low.
• 25-hydroxyvitamin D: Target above 30 ng/mL (75 nmol/L) before restarting. Vitamin D insufficiency potentiates hypocalcemia risk and attenuates BMD response to alendronate.
• Albumin: Needed to correctly interpret total serum calcium; use the standard correction formula: corrected calcium = measured calcium + 0.8 × (4.0 minus measured albumin in g/dL).

Functional and GI Prerequisites

Before the first restart dose:

1. The patient must be able to sit or stand fully upright for 30 minutes without assistance.
2. The patient must be able to swallow a tablet with at least 6 oz (180 mL) of plain water.
3. Active esophageal symptoms (heartburn, dysphagia, odynophagia) must be resolved or investigated.
4. Oral intake of food and other medications must be delayed at least 30 to 60 minutes after the alendronate dose.

The ACR 2022 Guideline on the Management of Osteoporosis in Adults states: "Bisphosphonate therapy should not be initiated or reinitiated in patients with known esophageal abnormalities that delay esophageal emptying."

Medication Review

Acute illness hospitalization often introduces new medications. Review for interactions before restarting alendronate:

• Calcium supplements and antacids: Space at least 2 hours after alendronate.
• Oral iron and multivitamins: Take at least 60 minutes after alendronate.
• NSAIDs: Concurrent use may increase GI mucosal injury risk; reassess necessity.
• Proton pump inhibitors (PPIs): May slightly reduce alendronate absorption but are generally acceptable in patients with reflux history. A pharmacokinetic study in Clinical Pharmacology and Therapeutics found no clinically meaningful absorption change when PPIs were timed appropriately.

Restart Dosing Protocol

No dose escalation is needed. The restart dose is the same as the maintenance dose the patient was receiving before the hold.

Standard Doses

• Osteoporosis treatment (postmenopausal women or men): 70 mg orally once weekly or 10 mg orally once daily.
• Osteoporosis prevention: 35 mg orally once weekly or 5 mg orally once daily.
• Glucocorticoid-induced osteoporosis: 5 mg daily (or 10 mg daily in postmenopausal women not on estrogen).

The FDA-approved prescribing information does not describe a loading dose or re-initiation protocol distinct from standard initiation, because the drug's binding kinetics in bone do not require re-loading after a short hold.

Timing Relative to Illness Resolution

| Clinical Scenario | Recommended Restart Timing | |---|---| | Acute GI illness (gastroenteritis), resolved | 48 to 72 hours after resolution of vomiting and return to normal oral intake | | Hospitalization for orthopedic surgery | After patient can sit/stand for 30 min; typically post-operative day 3 to 7 | | AKI with eGFR recovery above 35 | After two consecutive eGFR readings above 35, at least 1 week apart | | Pneumonia or respiratory illness | After full oral intake resumes and patient is ambulatory | | Hip fracture (the index fragility fracture) | Start or restart alendronate 2 to 4 weeks post-operatively per FLS protocol |

The Hip Fracture Special Case

Patients who experience a hip fracture while already on alendronate raise a specific question: should the drug be changed, or simply restarted? An American Society for Bone and Mineral Research task force report recommended that hip fracture patients be evaluated for secondary causes of bone loss and that bisphosphonate therapy be continued or reinitiated unless a specific contraindication exists. Fractures on therapy do not by themselves indicate treatment failure when adherence was suboptimal or co-morbidities were present.

Special Populations Requiring Modified Restart Approaches

Older Adults (Age 75 and Above)

Age 75 and older patients have higher background rates of esophageal dysmotility, renal impairment, and vitamin D deficiency. A cohort analysis published in Osteoporosis International found that adherence to correct dosing instructions dropped substantially with increasing age and cognitive impairment. For these patients, a caregiver education session or a nurse-led medication instruction visit before restart is recommended.

Patients with Glucocorticoid Use

Long-term glucocorticoid therapy accelerates bone loss through multiple mechanisms including direct osteoblast suppression and secondary hypogonadism. ACR guidelines specify that patients receiving prednisone 2.5 mg/day or more for 3 months or longer should be on anti-resorptive therapy, making prompt restart after acute illness especially time-sensitive in this group.

Post-Bariatric Surgery Patients

Patients who have undergone Roux-en-Y gastric bypass have severely impaired alendronate absorption due to loss of the proximal small intestine absorptive surface. A pharmacokinetic study showed oral bisphosphonate bioavailability is reduced by more than 50% after gastric bypass. For these patients, intravenous zoledronic acid 5 mg once yearly is generally preferred over oral alendronate restart.

Patients with Atrial Fibrillation

Early case reports raised concerns about a possible association between bisphosphonate use and atrial fibrillation. A large analysis published in the New England Journal of Medicine (N=6,459) found that serious atrial fibrillation occurred more frequently in the zoledronic acid group (1.3% vs. 0.5%, P<0.001). For oral alendronate, the evidence is less clear, but a meta-analysis in Archives of Internal Medicine found no statistically significant increase in atrial fibrillation risk. Alendronate restart is not contraindicated in stable atrial fibrillation.

Monitoring After Restart

Routine monitoring after restarting alendronate following an illness-related hold follows the same schedule as de novo initiation monitoring.

Bone Mineral Density

The Endocrine Society Clinical Practice Guideline on osteoporosis recommends repeat DXA scanning after 1 to 2 years of therapy to assess treatment response. After a short hold of less than 3 months, repeating DXA earlier than the scheduled interval is generally not indicated unless a new fragility fracture occurred during the hold.

Bone Turnover Markers

Serum CTX or procollagen type 1 N-terminal propeptide (P1NP) can confirm re-engagement of the antiresorptive effect. Expect CTX to fall by 50 to 70% from baseline within 3 to 6 months of restarting. A 2019 Lancet review on osteoporosis management endorsed bone turnover markers as the most responsive short-term indicators of bisphosphonate efficacy.

When to Switch Agents After a Hold

A short hold does not usually justify switching agents. Switching to denosumab (Prolia, 60 mg subcutaneous every 6 months) may be considered when:

• The patient cannot reliably maintain upright posture after dosing (e.g., progressive spinal disease).
• Recurrent GI intolerance makes continued oral bisphosphonate use impractical.
• eGFR remains persistently below 35 mL/min/1.73 m² after recovery.

Switching to intravenous zoledronic acid (Reclast, 5 mg once yearly) is preferred when bariatric anatomy or severe esophageal disease precludes oral administration.

Drug Holiday Considerations: Does a Forced Hold Count?

An illness-related hold is not the same as a planned bisphosphonate drug holiday, but the clinical overlap is worth addressing directly. A drug holiday is a scheduled pause taken after 3 to 5 years of therapy in patients at lower ongoing fracture risk, designed to reduce the rare risk of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ). The ASBMR task force on long-term bisphosphonate therapy recommends reassessing continuation after 5 years for patients at low-to-moderate fracture risk (T-score above negative 2.5 at the hip, no vertebral fractures, no ongoing glucocorticoid use).

Forced Hold vs. Planned Holiday: A Decision Framework

Use the following to distinguish the two scenarios and determine the correct path forward:

Scenario A: Illness hold of <3 months, patient is high fracture risk Restart alendronate at the original dose as soon as clinical prerequisites are met. The hold was involuntary and the patient's fracture risk has not changed.

Scenario B: Illness hold of >3 months that coincides with 5-year treatment anniversary Treat this as an opportunity to conduct the formal drug holiday assessment. Obtain DXA, calculate FRAX with BMD, review AFF symptoms (prodromal thigh pain), and dental history.

Scenario C: Illness hold in patient who had already been on a planned holiday The holiday is ongoing. Restart criteria apply only if the clinical reassessment (DXA, FRAX, clinical risk factors) indicates treatment is needed again.

Atypical Femoral Fracture Risk Context

The absolute risk of AFF with alendronate is low but real. A Swedish cohort study (N=1,234 atypical femoral fractures) found the incidence rose from 1.8 per 100,000 person-years at 2 years of use to 113 per 100,000 person-years at 8 years or more. For a typical patient with 5 years of alendronate use, the absolute AFF risk remains well below 1 per 1,000 per year, far lower than the fracture risk prevented by the drug in high-risk individuals.

Patient Instructions for the Restart Dose

Patients need a concrete rehearsal of correct dosing technique at restart, especially after a hospital stay where they may have taken all medications with breakfast in bed.

Step-by-Step Dosing Instructions

1. Take the tablet on waking, before any food, drink (other than water), or other medications.
2. Swallow with a full glass of plain water, at least 6 oz (180 mL). Do not use mineral water, sparkling water, coffee, juice, or milk.
3. Remain standing or sitting fully upright, do not lie down, for 30 full minutes.
4. Do not eat or drink anything other than plain water for at least 30 minutes after taking the dose.
5. If a weekly dose is missed, take it the morning after you remember, then return to the weekly schedule. Do not take two doses in one day.

FDA-approved patient labeling requires these instructions to be reviewed with patients at initiation and any time there has been a significant gap in therapy.

Adherence After an Illness-Related Gap

Adherence to weekly alendronate drops substantially after any treatment interruption. A large retrospective cohort study published in Osteoporosis International (N=38,120) found that medication possession ratio (MPR) below 0.80 was associated with a 17% increase in hip fracture risk compared with fully adherent patients. Patients who experienced a hospitalization were among those with the lowest MPR at 12-month follow-up.

Strategies that improve post-illness re-adherence include:

• Setting a recurring calendar alert for the weekly dose day.
• Designating a specific pill location visible from the bathroom sink.
• Coordinating with the discharging pharmacist to fill the alendronate prescription as part of hospital discharge medications.
• A follow-up phone call or telehealth visit at 30 days post-discharge to confirm restart and correct technique.